Type 2 diabetes: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• GLP-1 66
• SGLT2 41
• PPAR 0
• AMPK 2
• DPP-4 7
• PI3K 0
• AKT 0
• GIP 4
• mTOR 0
• NRF2 0
• NLRP3 3
• SIRT1 1
• STAT3 0
• TP53 1
• TNF 0
• MAPK 0
• PCSK9 1
• VEGF 2
• JNK 0
• TLR4 0
• FTO 0
• IL-6 2
• ERK 0
• HIF-1 0
• JAK 0
• HMGB1 0
• APOE 0
• BDNF 0
• IL-1 1
• STING 0
• CTNNB1 0
• GPX4 0
• PTEN 0
• STK11 0
• IL-17 1
• MMP-9 1
• BCL-2 0
• COX-2 0
• MEK 0
• PINK1 0
• CD40 0
• EGFR 0
• PD-1 0
• RANKL 0
• YAP 0
• ATM 0
• FGFR 0
• MET 1
• PD-L1 0
• SNCA 0
• CCR5 0
• CDKN2A 0
• CXCR4 0
• IGF1R 0
• MAPT 0
• METTL3 0
• PNPLA3 0
• ABL1 0
• BACE1 0
• CD38 0

21 of 21+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glutaminase Isoenzymes: Gatekeepers of Bioenergetics, Immunity, and Tumor Microenvironment in Diabetes-Induced Hepatocellular Carcinoma (IRM)

  Fundacion Para la Investigacion de Malaga En Biomedicina y Salud· Malaga, Spain· EU contribution €209,915· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unmasking the Perivascular Adipose Tissue's Role in Diabetic Vascular Disease From Molecular Clues to Clinical Impact (IMAPERFAT)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €236,340· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Bridging Chronobiology and Physiology through Expert Training (ChronoBridge)

  Ecole Polytechnique Federale de Lausanne· Lausanne, Switzerland· EU contribution €3,885,022· until Dec 2030· 9 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  AI-Powered and Robot-Assisted Opto-Acoustic Evaluation of Systemic Microangiopathy for Ulcer Healing Outcomes in Type 2 Diabetes (ARETEOS)

  Universitatsklinikum Erlangen· Erlangen, Germany· EU contribution €1,499,068· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  First-in-man beta-cell regeneration for causal type 2 diabetes therapy (BetaProtect)

  Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit und Umwelt Gmbh· Neuherberg, Germany· EU contribution €150,000· until Apr 2028

5 of 59 running projects, newest first. Listed amounts together: €152.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

  NCT04906213· Duke University· Updated 27 Feb 2026

  “The study closed per PI decision due to completion of the biopsy substudy and slow accrual”Registry text, quoted unchanged. Source

• Terminated

  Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes

  NCT05139914· Boston University· Updated 11 Feb 2026

  “The study was halted early because of the inability to enroll participants.”Registry text, quoted unchanged. Source

• Withdrawn

  Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin

  NCT07057479· Eurofarma Laboratorios S.A.· Updated 18 Dec 2025

  “Strategic change in development priorities”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

  NCT06297603· Eli Lilly and Company· Source

• QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy

  NCT07775846· Huijie Zhang· Source

• A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

  NCT06534411· Novo Nordisk A/S· Source

• CGM Use in Adults With Type 2 Diabetes on Basal Insulin

  NCT05944432· Abbott Diabetes Care· Source

• A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

  NCT06109311· Eli Lilly and Company· Source

• Cranberry Proanthocyanidins and Lactobacilli for Recurrent UTI Prevention in Type 2 Diabetes

  NCT07832409· National Institute of Endocrinology, Georgia· Source

• Improving Coronary Vascular Health in Women

  NCT06843902· Massachusetts General Hospital· Source

• LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

  NCT05313529· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Source

• SGLTi, Hepatic Glucose Production and Ketogenesis

  NCT05960656· The University of Texas Health Science Center at San Antonio· Source

• SGLT2i, Pioglitazone, and Ketone Production in T2D

  NCT07053319· The University of Texas Health Science Center at San Antonio· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 26
• Organoids 3
• Mendelian Randomization Analysis 228
• CRISPR-Cas Systems 5
• Gene Expression Profiling 113
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 8
• Exome Sequencing 12
• Proteomics 148
• Metabolomics 202
• Mass Spectrometry 42
• Flow Cytometry 19
• Immunohistochemistry 50
• Xenograft Model Antitumor Assays 34
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 187
• Machine Learning 196
• Deep Learning 32
• Cohort Studies 1112
• Genome-Wide Association Study 315

• Neuroprotective and Anti-Inflammatory Effects of SOCS1 Mimetic Peptides in Mouse Diabetic Retinopathy.

  Invest Ophthalmol Vis Sci, Oct 2026

• Insulin Induces Outer Blood-Retinal Barrier Disruption via Downregulation of Claudin-19.

  Invest Ophthalmol Vis Sci, Apr 2026

• Comparison of Immunohistochemical and Histopathological Findings between Patients with Diabetic and Idiopathic Carpal Tunnel Syndrome.

  J Hand Surg Asian Pac Vol, Jan 2026

• Effect of Melatonin on the Expression of α2- and β1-Adrenergic Receptors in the Liver of db/db Mice. Immunohistochemical Characteristics.

  Bull Exp Biol Med, Nov 2025

• Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma.

  Front Endocrinol (Lausanne), Feb 2022

• Effect of metformin treatment and its time of administration on joint capsular fibrosis induced by mouse knee immobilization.

  Sci Rep, Sept 2021

• Melatonin ameliorates diabetes-induced brain injury in rats.

  Acta Histochem, Jan 2021

• Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy.

  Int J Biol Sci, Mar 2019

• Distribution and density of melatonin receptors in human main pancreatic islet cell types.

  J Pineal Res, Mar 2018

• Diabetic Status Influences the Storage of Melatonin in Human Salivary Glands.

  Anat Rec (Hoboken), Dec 2017

See which targets of this disease your abstract mentions, and go to the people working on them.